RAPPORT THERAPEUTICS INC (RAPP)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Rapport Therapeutics is a clinical-stage biotech company advancing therapeutic candidates from its proprietary RAP technology platform toward regulatory approval.
What RAPPORT THERAPEUTICS INC does
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates based on its RAP technology platform. The company focuses on identifying, developing, and commercializing therapeutics for currently undisclosed indications. Rapport is advancing multiple preclinical and clinical programs through regulatory approval processes and has entered into licensing and collaboration agreements with partners including Janssen Pharmaceutical NV and Tenacia Biotechnology (Hong Kong) Co., Ltd.
Themes: ["Drug discovery and development","Biopharmaceutical innovation","Preclinical to clinical advancement"]
Fundamentals
- Price$42.05 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+232.7% as of 2026-07-09 close
- ROE-24.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.53 as of 2026-07-10
Key risks (from latest filing)
["Inability to demonstrate that product candidates are safe and effective for their proposed indications","Dependence on sufficient capital funding and ability to obtain additional financing for future operations and clinical trial expenses","Compliance and performance obligations under intellectual property licenses with third parties including Janssen Pharmaceutical NV and Tenacia Biotechnology"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.